Baculovirus-Mediated Gene Therapy: Targeting BIRC6 for Lung and Breast Cancer

• Autores: Marchesini, Abril; Gómez Bergna, Santiago Manuel; Amorós Morales, Leslie Cinthya; López, María Florencia; Vásquez, Larisa; Tongiani, Silvana E.; González Morán, Florencia; Romanowski, Víctor; Gottardo, María Florencia; Pidre, Matías Luis
• Año de publicación: 2025
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: Biología; BIRC6; baculovirus; shRNA; lung cancer; breast cancer; apoptosis
• Institución: Universidad Nacional de La Plata

BIRC6, a member of the inhibitor of apoptosis protein family (IAP), regulates apoptosis, autophagy and cytokinesis. IAPs are often overexpressed in tumors, contributing to oncogenesis, therapy resistance and worse prognosis. In particular, BIRC6 overexpression has been found in several tumor tissues. The aim of this study was to evaluate the effect of BIRC6 silencing on the apoptotic response of breast and lung tumor cells. We used RNA interference based on short hairpin RNA (shRNA) to knock down gene expression encoded by a recombinant baculovirus (BV), an insect-specific virus unable to replicate in mammalian hosts, to carry out preclinical validation tests in experimental models both in vitro and in vivo. Our results indicate that BIRC6 plays an antiapoptotic role in both breast and lung tumor cells. In vivo, treatment with BV-shBRIC6 reduced breast and lung tumor progression and increased overall survival. After histological analysis, BV-shBRIC6 was able to increase tumor necrosis. In addition, we demonstrated that BIRC6 expression correlates with antiapoptotic and tumor progression-relevant markers in lung and breast cancer patients. BV-based silencing of BIRC6 may have therapeutic value for the treatment of lung and breast tumors. Further translational studies of BV-shBIRC6 in lung and breast cancer are warranted.
Instituto de Biotecnología y Biología Molecular